🔬🧬 Hematology Updates: AbbVie’s $1.9B Myeloma Deal, 92% AML Remission, India Crisis and More
From AbbVie’s $1.9B antibody deal to China’s first Bcl-2 inhibitor approval and a public health emergency in Maharashtra—this week’s hematology roundup delivers critical breakthroughs, regulatory wins, and urgent updates driving blood cancer and rare disease innovation.
💡 Key Highlights This Week:
✅ AbbVie and IGI sign $1.9B deal for trispecific antibody ISB 2001 in relapsed/refractory multiple myeloma, showing 79% ORR in Phase 1
✅ IASO Bio’s CAR-T therapy Fucaso gains orphan status in South Korea following ≥3 prior MM therapies
🧪 Teclistamab demonstrates 53% disease reduction in high-risk multiple myeloma patients excluded from MajesTEC-1
💊 FDA accepts Taiho’s all-oral INQOVI + venetoclax combo for AML with 46.5% CR in elderly, chemo-ineligible patients
🌟 IDH1/2-mutant AML sees 92% complete remission with venetoclax + IDH inhibitor + HMA triplet; 2-year OS up to 84%
🇨🇳 Lisaftoclax approved as China’s first Bcl-2 inhibitor for CLL/SLL; no tumor lysis syndrome observed in trials
🇪🇺 EMA grants orphan designation to Nurix’s BTK degrader Bexobrutideg for Waldenström’s macroglobulinemia
🧫 NIH and Vascarta launch Phase 1 trial of VAS-101 curcumin gel for sickle cell disease targeting pain and RBC health
🇪🇺 Lobe Sciences secures EU patent across 17 countries for DHA-based Altemia® formulation in sickle cell deficiency
⚠️ Maharashtra faces hemophilia crisis: 30 deaths reported due to clotting factor shortages; no supply in public hospitals since Sept 2024
🎯 Whether you’re tracking CAR-T approvals, Bcl-2 innovations, or AML regimen advances—this episode delivers essential insights for hematology researchers, clinicians, and biotech leaders.
📢 Stay Ahead in Hematology Research!
✅ Like, share, and subscribe for weekly updates on hematology breakthroughs and blood disorder innovation
#Hematology #MultipleMyeloma #AML #CLL #SickleCellDisease #CAR_T #BTKDegrader #Bcl2Inhibitor #OrphanDrug #BloodCancer #LucidQuest #HematologyUpdates #NIH #BiopharmaNews #ClinicalTrials #DrugDevelopment #HealthcareInnovation #RareDiseases #PublicHealthCrisis